Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Takeda Pharmaceutical Company Limited
  6. Summary
    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
11/19/2021 11/22/2021 11/24/2021 11/25/2021 11/26/2021 Date
3227 3185 3163 3156 3136 Last
4085100 9055400 7086100 4932100 7146700 Volume
-0.37% -1.30% -0.69% -0.22% -0.63% Change
Estimated financial data (e)
Sales 2022 3 407 B 30 070 M 30 070 M
Net income 2022 223 B 1 964 M 1 964 M
Net Debt 2022 3 334 B 29 426 M 29 426 M
P/E ratio 2022 21,9x
Yield 2022 5,74%
Sales 2023 3 408 B 30 072 M 30 072 M
Net income 2023 327 B 2 887 M 2 887 M
Net Debt 2023 2 870 B 25 328 M 25 328 M
P/E ratio 2023 14,9x
Yield 2023 5,74%
Capitalization 4 932 B 43 512 M 43 528 M
EV / Sales 2022 2,43x
EV / Sales 2023 2,29x
Nbr of Employees 47 099
Free-Float 98,2%
More Financials
Company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system... 
Sector
Pharmaceuticals
Calendar
02/03 | 01:00amEarnings Release
More about the company
Ratings of Takeda Pharmaceutical Company Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
11/24Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment ..
AQ
11/24FDA Approves Takeda Drug Livtencity for Post-Transplant CMV Infection
MT
11/24Takeda Gets US FDA Nod on Treatment for Cytomegalovirus
MT
11/23U.S. FDA approves Takeda's drug for post-transplant CMV infection
RE
11/23Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment ..
BU
11/23Takeda?s LIVTENCITYTM Approves by U.S. FDA as the First and Only Treatment for People A..
CI
11/23TAKEDA PHARMACEUTICAL : LIVTENCITY (maribavir) Approved by U.S. FDA as the First and Only ..
PU
11/23U.S. FDA approves Takeda's drug for post-transplant infection
RE
11/22Kamada Shares Up After Buying Portfolio From Saol Therapeutics
DJ
11/17Denali Says Takeda to Co-Develop, Co-Commercialize DNL593 Frontotemporal Dementia Inves..
MT
11/17Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop a..
CI
11/17Canadian Blood Services Awards Takeda Canada Three-Year Tender for Hemophilia treatment..
AQ
11/16HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful ..
CI
11/11Japan's Takeda applies for gov't approval of Moderna's booster shots
AQ
11/05Quarterly Securities Report(The second quarter of 145th Business Term) for The Six-mont..
PU
More news
News in other languages on TAKEDA PHARMACEUTICAL COMPANY LIMITED
11/24La FDA approuve le médicament Livtencity de Takeda pour l'infection à CMV post-transpla..
11/17Denali et Takeda vont co-développer et co-commercialiser le traitement expérimental DNL..
11/02Takeda beantragte die Auswahl des „Prime Market“, reichte einen Corporate G..
11/02Takeda se postuló para la selección de “mercado principal” y presentó el In..
10/30Takeda logra sólidos resultados en el primer semestre del año fiscal 2021; se espera un..
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 136,00 JPY
Average target price 4 322,86 JPY
Spread / Average Target 37,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-16.48%43 512
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049